Method for optimally preparing lornoxicam flexible liposome with Box-Behnken response surface method

Abstract

The invention aims at providing a method for preparing an optimal preparation of lornoxicam flexible liposome in a screening mode with the Box-Behnken response surface method. The response surface method has the advantages that experiment design is comprehensive, scientific and accurate, and the interaction of multiple factors can be studied. According to the method, four factors including the phospholipid concentration, the phospholipid-cholesterol mass ratio, the total lipid-Tween 80 mass ratio and the total lipid-medicine mass ratio which influence the flexible liposome preparing process greatly are investigated separately, Box-Behnken response surface experiment design is conducted with the encapsulation rate and the particle size as the optimization indexes, and the optimal preparation of the lornoxicam flexible liposome is obtained through optimization. The lornoxicam flexible liposome obtained through optimization is high in encapsulation rate and uniform in size distribution and has the characteristic of slow release, which provides a good experimental basis for the process of preparing the lornoxicam flexible liposome into hydrophilic gel at the later stage.

Description

technical field [0001] The invention belongs to the field of medicines, and particularly provides a method for optimizing the preparation of lornoxicam flexible liposomes by using the Box-Behnken effect surface method. Background technique [0002] Lornoxicam is a non-steroidal anti-inflammatory drug with anti-inflammatory, analgesic and antipyretic effects, and can highly selectively inhibit cyclooxygenase inhibitors (COX-II). Clinically, it is mainly used for chronic joint inflammation, pain after surgery and acute trauma, and fever caused by upper respiratory tract infection. At present, lornoxicam has clinical dosage forms such as tablets, granules and dry suspensions, but due to its small solubility, low bioavailability, large fluctuations, and low local concentration, frequent administration is required. There are certain adverse reactions in the gastrointestinal tract, and the liver toxicity is relatively large. [0003] As a drug carrier for external use, liposome ...

AI Technical Summary

Problems solved by technology

At present, lornoxicam has clinical dosage forms such as tablets, granules and dry suspensions, but due to its small solubility, low bioavailability, large fluctuations, and low local concentration, frequent administration is required. There are certain adverse reactions in the gastrointestinal tract, and the liver is more toxic

Images